These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38708001)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stiff person syndrome masquerading as multiple sclerosis.
    Sabatino JJ; Newsome SD
    J Neurol Sci; 2017 Jan; 372():297-299. PubMed ID: 28017232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of symptoms associated with spasticity in patients with multiple sclerosis].
    Fernández-Pablos MA; Costa-Frossard L; García-Hernández C; García-Montes I; Escutia-Roig M;
    Enferm Clin; 2016; 26(6):367-373. PubMed ID: 27492746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptomatic therapy of multiple sclerosis.
    Markowitz C
    Continuum (Minneap Minn); 2010 Oct; 16(5 Multiple Sclerosis):90-104. PubMed ID: 22810600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study.
    Marinelli L; Puce L; Mori L; Leandri M; Rosa GM; Currà A; Fattapposta F; Trompetto C
    Front Neurol; 2022; 13():892165. PubMed ID: 35812088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabis and multiple sclerosis.
    Fragoso YD; Carra A; Macias MA
    Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of an integrated conceptual model of multiple sclerosis spasticity.
    Cameron MH; Bethoux F; Field-Fote E; Lenderking WR; Zaiser E; Cutts KN; Wagner JM; Berwaerts J; Steinerman JR
    Disabil Rehabil; 2024 Jun; 46(13):2955-2965. PubMed ID: 37480330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
    [No Abstract]   [Full Text] [Related]  

  • 31. A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm.
    Tolley C; Piani-Meier D; Bentley S; Bennett B; Jones E; Pike J; Dahlke F; Tomic D; Ziemssen T
    JMIR Med Inform; 2020 Apr; 8(4):e17592. PubMed ID: 32286236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
    Bethoux F; Marrie RA
    Patient; 2016 Dec; 9(6):537-546. PubMed ID: 27154536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing the symptoms of multiple sclerosis: a multimodal approach.
    Crayton HJ; Rossman HS
    Clin Ther; 2006 Apr; 28(4):445-60. PubMed ID: 16750459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).
    Hobart JC; Riazi A; Thompson AJ; Styles IM; Ingram W; Vickery PJ; Warner M; Fox PJ; Zajicek JP
    Brain; 2006 Jan; 129(Pt 1):224-34. PubMed ID: 16280352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
    Haas J
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):3-8. PubMed ID: 21449853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do cannabinoids reduce multiple sclerosis-related spasticity?
    Thaera GM; Wellik KE; Carter JL; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2009 Nov; 15(6):369-71. PubMed ID: 19901724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.